• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

产超广谱β-内酰胺酶菌株的治疗选择。

Treatment options for extended-spectrum beta-lactamase-producers.

作者信息

Essack S Y

机构信息

School of Pharmacy and Pharmacology, University of Durban-Westville, South Africa.

出版信息

FEMS Microbiol Lett. 2000 Sep 15;190(2):181-4. doi: 10.1111/j.1574-6968.2000.tb09283.x.

DOI:10.1111/j.1574-6968.2000.tb09283.x
PMID:11034276
Abstract

A review of antibiotic options for the treatment of infections caused by extended-spectrum beta-lactamase-producing isolates is presented. The use of the third-generation cephalosporin, cefotaxime, for infections caused by isolates producing ceftazidimase-type extended-spectrum beta-lactamases is controversial, despite in vitro susceptibility to the antibiotic in many instances. The fourth-generation cephalosporin, cefipime, although active against most extended-spectrum beta-lactamases, is reported to show a marked inoculum effect. The cephamycins, such as cefoxitin. are generally effective against Enterobacteriaceae producing TEM- and SHV-derived extended-spectrum beta-lactamases, but Klebsella pneumoniae strains are prone to cephamycin resistance as a result of porin loss. The use of beta-lactamase inhibitor combinations is variable. Sulbactam is less effective than clavulanate for the inhibition of SHV-derived extended-spectrum beta-lactamases and a marked inoculum effect has been noted, while the efficacy of tazobactam against SHV-derived extended-spectrum beta-lactamase producers is controversial. Furthermore, extended-spectrum beta-lactamases are often encoded by multi-resistant plasmids carrying genes conferring resistance to aminoglycosides, chloramphenicol, sulfonamides, trimethoprim and other antimicrobials, severely limiting even alternative therapies. Extensive susceptibility testing before the institution of antibiotic therapy is thus vital.

摘要

本文综述了治疗产超广谱β-内酰胺酶菌株所致感染的抗生素选择。对于产头孢他啶酶型超广谱β-内酰胺酶的菌株所致感染,使用第三代头孢菌素头孢噻肟存在争议,尽管在许多情况下该菌株对这种抗生素在体外敏感。第四代头孢菌素头孢吡肟虽然对大多数超广谱β-内酰胺酶有活性,但据报道其存在明显的接种量效应。头霉素类,如头孢西丁,通常对产TEM型和SHV型超广谱β-内酰胺酶的肠杆菌科细菌有效,但肺炎克雷伯菌菌株由于孔蛋白缺失容易对头霉素耐药。β-内酰胺酶抑制剂联合用药的效果不一。舒巴坦对抑制SHV型超广谱β-内酰胺酶的效果不如克拉维酸,且已注意到明显的接种量效应,而他唑巴坦对产SHV型超广谱β-内酰胺酶菌株的疗效存在争议。此外,超广谱β-内酰胺酶通常由携带赋予对氨基糖苷类、氯霉素、磺胺类、甲氧苄啶和其他抗菌药物耐药性基因的多重耐药质粒编码,这严重限制了甚至替代疗法的应用。因此,在开始抗生素治疗前进行广泛的药敏试验至关重要。

相似文献

1
Treatment options for extended-spectrum beta-lactamase-producers.产超广谱β-内酰胺酶菌株的治疗选择。
FEMS Microbiol Lett. 2000 Sep 15;190(2):181-4. doi: 10.1111/j.1574-6968.2000.tb09283.x.
2
[Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].[革兰氏阴性菌临床上重要的β-内酰胺酶:超广谱β-内酰胺酶(ESBL)]
Epidemiol Mikrobiol Imunol. 2007 Aug;56(3):103-11.
3
Prevalence and antibacterial resistance patterns of extended-spectrum beta-lactamase producing Gram-negative bacteria isolated from ocular infections.从眼部感染中分离出的产超广谱β-内酰胺酶革兰氏阴性菌的患病率及抗菌耐药模式
Indian J Ophthalmol. 2016 Apr;64(4):303-11. doi: 10.4103/0301-4738.182943.
4
β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview.β-内酰胺酶介导的耐药性:生化、流行病学和遗传学概述。
Curr Pharm Des. 2013;19(2):164-208.
5
[Study on prevalence and molecular mechanisms of antibacterial resistance in Gram-negative pathogens of nosocomial infections in hospitals of Moscow and Perm'].[莫斯科和彼尔姆市医院医院感染革兰氏阴性病原菌抗菌药物耐药性的流行情况及分子机制研究]
Antibiot Khimioter. 2007;52(7-8):10-6.
6
[Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].[肠杆菌科细菌对β-内酰胺酶抗生素的耐药机制]
Acta Med Croatica. 2004;58(4):307-12.
7
Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.产超广谱β-内酰胺酶(ESBL)和产AmpC酶细菌的治疗选择。
Expert Opin Pharmacother. 2016;17(7):953-67. doi: 10.1517/14656566.2016.1154538. Epub 2016 Mar 3.
8
Sulbactam-containing beta-lactamase inhibitor combinations.含舒巴坦的β-内酰胺酶抑制剂复方制剂
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:185-8. doi: 10.1111/j.1469-0691.2007.01847.x.
9
Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.β-内酰胺类与β-内酰胺酶抑制剂联合制剂:抗菌活性及酶抑制效果
Am J Health Syst Pharm. 1995 Mar 15;52(6 Suppl 2):S15-22. doi: 10.1093/ajhp/52.6_Suppl_2.S15.
10
beta-Lactamases of increasing clinical importance.临床重要性日益增加的β-内酰胺酶。
Curr Pharm Des. 1999 Nov;5(11):839-45.

引用本文的文献

1
Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study.头孢西丁治疗重症患者中对头孢西丁敏感的产超广谱β-内酰胺酶肠杆菌科细菌感染的药代动力学、疗效及耐受性:一项回顾性单中心研究
Ann Intensive Care. 2022 Sep 30;12(1):90. doi: 10.1186/s13613-022-01059-9.
2
High Prevalence of Extended-Spectrum Beta-Lactamases in Strains Collected From Strictly Defined Community-Acquired Urinary Tract Infections in Adults in China: A Multicenter Prospective Clinical Microbiological and Molecular Study.中国成人严格定义的社区获得性尿路感染分离菌株中超广谱β-内酰胺酶的高流行率:一项多中心前瞻性临床微生物学和分子研究
Front Microbiol. 2021 Jul 7;12:663033. doi: 10.3389/fmicb.2021.663033. eCollection 2021.
3
Mechanisms of Resistance in Gram-Negative Urinary Pathogens: From Country-Specific Molecular Insights to Global Clinical Relevance.革兰氏阴性尿路病原体的耐药机制:从特定国家的分子见解到全球临床相关性
Diagnostics (Basel). 2021 Apr 28;11(5):800. doi: 10.3390/diagnostics11050800.
4
Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014.2010年至2014年间从中国尿路感染患者中分离出的需氧和兼性革兰氏阴性杆菌的抗菌药敏性
BMC Infect Dis. 2017 Mar 6;17(1):192. doi: 10.1186/s12879-017-2296-x.
5
Characterization of the extended-spectrum β-lactamases and determination of the virulence factors of uropathogenic Escherichia coli strains isolated from children.从儿童分离的产超广谱β-内酰胺酶大肠埃希菌的耐药特征及毒力因子分析。
Wien Klin Wochenschr. 2012 Aug;124(15-16):504-15. doi: 10.1007/s00508-012-0210-5. Epub 2012 Aug 16.
6
The Prevalence of ESBLs Producing Klebsiella pneumoniae Isolates in Some Major Hospitals, Iran.伊朗部分主要医院产超广谱β-内酰胺酶肺炎克雷伯菌分离株的流行情况
Open Microbiol J. 2011;5:91-5. doi: 10.2174/1874285801105010091. Epub 2011 Aug 16.
7
Multiplex asymmetric PCR-based oligonucleotide microarray for detection of drug resistance genes containing single mutations in Enterobacteriaceae.基于多重不对称PCR的寡核苷酸微阵列用于检测肠杆菌科中含有单突变的耐药基因。
Antimicrob Agents Chemother. 2007 Oct;51(10):3707-13. doi: 10.1128/AAC.01461-06. Epub 2007 Jul 23.
8
Clinical role of beta-lactam/beta-lactamase inhibitor combinations.β-内酰胺类/β-内酰胺酶抑制剂联合制剂的临床作用。
Drugs. 2003;63(14):1511-24. doi: 10.2165/00003495-200363140-00006.